Liisa Bayko
Stock Analyst at Evercore ISI Group
(1.88)
# 3,096
Out of 4,884 analysts
83
Total ratings
55.22%
Success rate
n/a
Average return
Main Sectors:
Top Industries:
Stocks Rated by Liisa Bayko
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SVRA Savara | Maintains: In-Line | $3 → $2 | $2.19 | -8.68% | 4 | May 28, 2025 | |
| CRSP CRISPR Therapeutics AG | Upgrades: Outperform | $60 → $99 | $52.17 | +89.76% | 2 | Feb 14, 2025 | |
| TVTX Travere Therapeutics | Maintains: Outperform | $33 → $45 | $15.01 | +199.80% | 5 | Feb 12, 2025 | |
| BCRX BioCryst Pharmaceuticals | Maintains: Outperform | $10 → $12 | $8.94 | +34.23% | 5 | Jan 13, 2025 | |
| EDIT Editas Medicine | Maintains: Outperform | $7 → $5 | $2.57 | +94.55% | 5 | Dec 16, 2024 | |
| CARM Carisma Therapeutics | Downgrades: In-Line | $4 → $0.7 | $0.40 | +73.70% | 2 | Dec 11, 2024 | |
| KNSA Kiniksa Pharmaceuticals International, | Maintains: Outperform | $30 → $35 | $27.88 | +25.54% | 4 | Oct 30, 2024 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Outperform | $405 → $360 | $298.87 | +20.45% | 9 | Aug 8, 2024 | |
| VRTX Vertex Pharmaceuticals | Maintains: Outperform | $438 → $515 | $459.62 | +12.05% | 18 | Aug 2, 2024 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Outperform | $210 → $260 | $331.91 | -21.67% | 1 | Jun 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: In-Line | $7 → $2 | $1.05 | +90.48% | 3 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $37 → $33 | $10.16 | +224.80% | 4 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $50 → $38 | $51.77 | -26.60% | 3 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $60 → $80 | $39.91 | +100.45% | 8 | Jun 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $18 | $5.81 | +209.81% | 1 | Mar 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $14 → $25 | $4.76 | +425.21% | 1 | Jan 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $62 | $7.89 | +685.80% | 4 | Jul 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $35 | $6.56 | +433.54% | 1 | Nov 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $24 | $24.00 | - | 1 | Jun 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | $30 | $11.15 | +169.06% | 1 | Nov 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Market Outperform | $10 | $3.24 | +208.64% | 1 | Feb 5, 2020 |
Savara
May 28, 2025
Maintains: In-Line
Price Target: $3 → $2
Current: $2.19
Upside: -8.68%
CRISPR Therapeutics AG
Feb 14, 2025
Upgrades: Outperform
Price Target: $60 → $99
Current: $52.17
Upside: +89.76%
Travere Therapeutics
Feb 12, 2025
Maintains: Outperform
Price Target: $33 → $45
Current: $15.01
Upside: +199.80%
BioCryst Pharmaceuticals
Jan 13, 2025
Maintains: Outperform
Price Target: $10 → $12
Current: $8.94
Upside: +34.23%
Editas Medicine
Dec 16, 2024
Maintains: Outperform
Price Target: $7 → $5
Current: $2.57
Upside: +94.55%
Carisma Therapeutics
Dec 11, 2024
Downgrades: In-Line
Price Target: $4 → $0.7
Current: $0.40
Upside: +73.70%
Kiniksa Pharmaceuticals International,
Oct 30, 2024
Maintains: Outperform
Price Target: $30 → $35
Current: $27.88
Upside: +25.54%
Madrigal Pharmaceuticals
Aug 8, 2024
Maintains: Outperform
Price Target: $405 → $360
Current: $298.87
Upside: +20.45%
Vertex Pharmaceuticals
Aug 2, 2024
Maintains: Outperform
Price Target: $438 → $515
Current: $459.62
Upside: +12.05%
Alnylam Pharmaceuticals
Jun 25, 2024
Maintains: Outperform
Price Target: $210 → $260
Current: $331.91
Upside: -21.67%
May 16, 2024
Maintains: In-Line
Price Target: $7 → $2
Current: $1.05
Upside: +90.48%
May 15, 2024
Maintains: Outperform
Price Target: $37 → $33
Current: $10.16
Upside: +224.80%
May 15, 2024
Maintains: Outperform
Price Target: $50 → $38
Current: $51.77
Upside: -26.60%
Jun 6, 2023
Upgrades: Outperform
Price Target: $60 → $80
Current: $39.91
Upside: +100.45%
Mar 28, 2023
Initiates: Outperform
Price Target: $18
Current: $5.81
Upside: +209.81%
Jan 18, 2023
Maintains: Outperform
Price Target: $14 → $25
Current: $4.76
Upside: +425.21%
Jul 6, 2022
Upgrades: Outperform
Price Target: $62
Current: $7.89
Upside: +685.80%
Nov 23, 2021
Initiates: Outperform
Price Target: $35
Current: $6.56
Upside: +433.54%
Jun 8, 2021
Initiates: Outperform
Price Target: $24
Current: $24.00
Upside: -
Nov 24, 2020
Reinstates: Outperform
Price Target: $30
Current: $11.15
Upside: +169.06%
Feb 5, 2020
Upgrades: Market Outperform
Price Target: $10
Current: $3.24
Upside: +208.64%